Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances

Abstract

Ulcerative Colitis (UC) known as a sub-category of Inflammatory Bowel Diseases (IBD) is a long-term condition that causes inflammation, irritation, and ulcers in the colon and rectum. Though the precise pathogenesis of UC is not fully understood yet, impaired immune responses and imbalanced intestinal microbiome composition have been regarded as two main key players in colitis pathobiology. As conventional treatments are challenged with limitations and side effects, finding a new therapeutic approach has gained increasing attention. Probiotic bacteria with multifunctional health-promoting properties have been considered novel therapeutic options. There is strong evidence indicating that probiotics exert their therapeutic effects mostly by regulating immune system responses and restoring gut microbiome homeostasis. These results validate the rationale behind the clinical application of probiotics in UC management whether prescribed alone or in combination with conventional therapy. This article explores the pathogenesis of UC, concentrating on the influence of immune dysregulation and intestinal microbiome imbalances. Also, it reviews recent , and clinical studies that have demonstrated the efficacy of species in decreasing UC symptoms by modifying immune responses, restoring gut microbiota balance, and promoting intestinal barrier function.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128322653240925115114
2024-10-08
2024-11-21

  • From This Site

    /content/journals/cpd/10.2174/0113816128322653240925115114
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Gajendran M. Loganathan P. Jimenez G. Catinella A.P. Ng N. Umapathy C. Ziade N. Hashash J.G. A comprehensive review and update on ulcerative colitis. Dis. Mon. 2019 65 12 100851 10.1016/j.disamonth.2019.02.004 30837080
    [Google Scholar]
  2. Magro F. Langner C. Driessen A. Ensari A. Geboes K. Mantzaris G.J. Villanacci V. Becheanu G. Nunes P.B. Cathomas G. Fries W. Jouret-Mourin A. Mescoli C. de Petris G. Rubio C.A. Shepherd N.A. Vieth M. Eliakim R. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis 2013 7 10 827 851 10.1016/j.crohns.2013.06.001 23870728
    [Google Scholar]
  3. Kaur L Gordon M Baines PA Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2020 3 3 CD005573 10.1002/14651858.CD005573.pub3
    [Google Scholar]
  4. Tripathi K. Feuerstein J.D. New developments in ulcerative colitis: Latest evidence on management, treatment, and maintenance. Drugs Context 2019 8 1 11 10.7573/dic.212572 31065290
    [Google Scholar]
  5. Sharma N. Sharma A. Bhatnagar A. Nishad D. Karwasra R. Khanna K. Sharma D. Kumar N. Jain G.K. Novel gum acacia based macroparticles for colon delivery of Mesalazine: Development and gammascintigraphy study. J. Drug Deliv. Sci. Technol. 2019 54 101224 10.1016/j.jddst.2019.101224
    [Google Scholar]
  6. Hirankarn N. Kimkong I. Kummee P. Tangkijvanich P. Poovorawan Y. Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J. Gastroenterol. 2006 12 5 776 779 10.3748/wjg.v12.i5.776 16521194
    [Google Scholar]
  7. Ni J. Wu G.D. Albenberg L. Tomov V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017 14 10 573 584 10.1038/nrgastro.2017.88 28743984
    [Google Scholar]
  8. Schwartz M. Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 2008 10 6 585 590 10.1007/s11894‑008‑0106‑8 19006615
    [Google Scholar]
  9. Wilson D.C. Thomas A.G. Croft N.M. Newby E. Akobeng A.K. Sawczenko A. Fell J.M.E. Murphy M.S. Beattie R.M. Sandhu B.K. Mitton S.G. Casson D. Elawad M. Heuschkel R. Jenkins H. Johnson T. Macdonald S. Murch S.H. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2010 50 S1 S14 S34 10.1097/MPG.0b013e3181c92caa 20081542
    [Google Scholar]
  10. Ungaro R. Mehandru S. Allen P.B. Peyrin-Biroulet L. Colombel J.F. Ulcerative colitis. Lancet 2017 389 10080 1756 1770 10.1016/S0140‑6736(16)32126‑2 27914657
    [Google Scholar]
  11. Colombel J.F. Sands B.E. Rutgeerts P. Sandborn W. Danese S. D’Haens G. Panaccione R. Loftus E.V. Jr Sankoh S. Fox I. Parikh A. Milch C. Abhyankar B. Feagan B.G. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017 66 5 839 851 10.1136/gutjnl‑2015‑311079 26893500
    [Google Scholar]
  12. Sandborn W.J. Su C. Sands B.E. D’Haens G.R. Vermeire S. Schreiber S. Danese S. Feagan B.G. Reinisch W. Niezychowski W. Friedman G. Lawendy N. Yu D. Woodworth D. Mukherjee A. Zhang H. Healey P. Panés J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2017 376 18 1723 1736 10.1056/NEJMoa1606910 28467869
    [Google Scholar]
  13. Nishida A. Inoue R. Inatomi O. Bamba S. Naito Y. Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 2018 11 1 1 10 10.1007/s12328‑017‑0813‑5 29285689
    [Google Scholar]
  14. Matthes H. Krummenerl T. Giensch M. Wolff C. Schulze J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement. Altern. Med. 2010 10 1 13 10.1186/1472‑6882‑10‑13 20398311
    [Google Scholar]
  15. Sharma N. Arora A. Kakkar D. Natural polysaccharides for ulcerative colitis: A general overview. Asian Pac. J. Trop. Biomed. 2023 13 5 185 194 10.4103/2221‑1691.377405
    [Google Scholar]
  16. Zhu L.R. Li S.S. Zheng W.Q. Ni W.J. Cai M. Liu H.P. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front. Immunol. 2023 14 1086078 10.3389/fimmu.2023.1086078 36817459
    [Google Scholar]
  17. Alagiakrishnan K. Morgadinho J. Halverson T. Approach to the diagnosis and management of dysbiosis. Front. Nutr. 2024 11 1330903 10.3389/fnut.2024.1330903 38706561
    [Google Scholar]
  18. Alshehri D. Saadah O. Mosli M. Edris S. Alhindi R. Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn. J. Basic Med. Sci. 2021 21 3 270 283 33052081
    [Google Scholar]
  19. De Filippis A. Ullah H. Baldi A. Dacrema M. Esposito C. Garzarella E.U. Santarcangelo C. Tantipongpiradet A. Daglia M. Gastrointestinal disorders and metabolic syndrome: Dysbiosis as a key link and common bioactive dietary components useful for their treatment. Int. J. Mol. Sci. 2020 21 14 4929 10.3390/ijms21144929 32668581
    [Google Scholar]
  20. Zakerska-Banaszak O. Tomczak H. Gabryel M. Baturo A. Wolko L. Michalak M. Malinska N. Mankowska-Wierzbicka D. Eder P. Dobrowolska A. Slomski R. Skrzypczak-Zielinska M. Dysbiosis of gut microbiota in polish patients with ulcerative colitis: A pilot study. Sci. Rep. 2021 11 1 2166 10.1038/s41598‑021‑81628‑3 33495479
    [Google Scholar]
  21. Talapko J. Včev A. Meštrović T. Pustijanac E. Jukić M. Škrlec I. Homeostasis and dysbiosis of the intestinal microbiota: Comparing hallmarks of a healthy state with changes in inflammatory bowel disease. Microorganisms 2022 10 12 2405 10.3390/microorganisms10122405 36557658
    [Google Scholar]
  22. Dhillon P. Singh K. Therapeutic applications of probiotics in ulcerative colitis: An updated review. PharmaNutrition 2020 13 100194 10.1016/j.phanu.2020.100194
    [Google Scholar]
  23. Chibbar R. Dieleman L.A. Probiotics in the management of ulcerative colitis. J. Clin. Gastroenterol. 2015 49 S50 S55 10.1097/MCG.0000000000000368 26447965
    [Google Scholar]
  24. van der Waal M.B. Flach J. Browne P.D. Besseling-van der Vaart I. Claassen E. van de Burgwal L.H.M. Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. PharmaNutrition 2019 7 100139 10.1016/j.phanu.2018.100139
    [Google Scholar]
  25. Murray A Nguyen TM Parker CE Feagan BG MacDonald JK Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst. Rev. 2020 8 8 CD000543 10.1002/14651858.CD000543.pub5
    [Google Scholar]
  26. Louis E. Paridaens K. Al Awadhi S. Begun J. Cheon J.H. Dignass A.U. Magro F. Márquez J.R. Moschen A.R. Narula N. Rydzewska G. Freddi M.J. Travis S.P.L. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol. 2022 9 1 e000853 10.1136/bmjgast‑2021‑000853 35165124
    [Google Scholar]
  27. Dorrington A.M. Selinger C.P. Parkes G.C. Smith M. Pollok R.C. Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J. Crohn’s Colitis 2020 14 9 1316 1329 10.1093/ecco‑jcc/jjaa053 32170314
    [Google Scholar]
  28. Calméjane L. Laharie D. Kirchgesner J. Uzzan M. Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies. United Eur. Gastroenterol. J. 2023 11 8 722 732 10.1002/ueg2.12442 37475143
    [Google Scholar]
  29. Singh S Allegretti JR Siddique SM Terdiman JP AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020 158 5 1465 1496.e17 10.1053/j.gastro.2020.01.007
    [Google Scholar]
  30. Chhibba T. Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin. Biol. Ther. 2020 20 4 379 390 10.1080/14712598.2020.1708896 31874578
    [Google Scholar]
  31. Zhou H.Y. Guo B. Lufumpa E. Li X.M. Chen L.H. Meng X. Li B.Z. Comparative of the effectiveness and safety of biological agents, tofacitinib, and fecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis. Immunol. Invest. 2021 50 4 323 337 10.1080/08820139.2020.1714650 32009472
    [Google Scholar]
  32. Singh S Facciorusso A Dulai PS Jairath V Sandborn WJ Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2020 18 1 69 81.e3 10.1016/j.cgh.2019.02.044
    [Google Scholar]
  33. Le B. Yang S.H. Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease. Toxicol. Rep. 2018 5 314 317 10.1016/j.toxrep.2018.02.007 29854599
    [Google Scholar]
  34. Sun M. Liu Y. Song Y. Gao Y. Zhao F. Luo Y. Qian F. Mu G. Tuo Y. The ameliorative effect of Lactobacillus plantarum -12 on DSS-induced murine colitis. Food Funct. 2020 11 6 5205 5222 10.1039/D0FO00007H 32458908
    [Google Scholar]
  35. Tanaka A. Kanmura S. Morinaga Y. Kawabata K. Arima S. Sasaki F. Nasu Y. Tanoue S. Hashimoto S. Takeshita M. Takeda S. Ido A. Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response. Mol. Med. Rep. 2020 21 3 1181 1191 10.3892/mmr.2020.10925 31922249
    [Google Scholar]
  36. Pan Y. Ning Y. Hu J. Wang Z. Chen X. Zhao X. The preventive effect of Lactobacillus plantarum ZS62 on DSS‐induced IBD by regulating oxidative stress and the immune response. Oxid. Med. Cell. Longev. 2021 2021 1 9416794 10.1155/2021/9416794 34745426
    [Google Scholar]
  37. Jin J. Wu S. Xie Y. Liu H. Gao X. Zhang H. Live and heat-killed cells of Lactobacillus plantarum Zhang-LL ease symptoms of chronic ulcerative colitis induced by dextran sulfate sodium in rats. J. Funct. Foods 2020 71 103994 10.1016/j.jff.2020.103994
    [Google Scholar]
  38. Zhang C. Zhao Y. Jiang J. Yu L. Tian F. Zhao J. Zhang H. Chen W. Zhai Q. Identification of the key characteristics of Bifidobacterium longum strains for the alleviation of ulcerative colitis. Food Funct. 2021 12 8 3476 3492 10.1039/D1FO00017A 33900330
    [Google Scholar]
  39. Yu P. Ke C. Guo J. Zhang X. Li B. Lactobacillus plantarum L15 alleviates colitis by inhibiting LPS-mediated NF-κB activation and ameliorates DSS-induced gut microbiota dysbiosis. Front. Immunol. 2020 11 575173 10.3389/fimmu.2020.575173 33123156
    [Google Scholar]
  40. Wang H. Zhou C. Huang J. Kuai X. Shao X. The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease. Am. J. Transl. Res. 2020 12 5 1569 1583 32509162
    [Google Scholar]
  41. Krishna M. Engevik M. Queliza K. Britto S. Shah R. Ruan W. Wang H. Versalovic J. Kellermayer R. Maternal Lactobacillus reuteri supplementation shifts the intestinal microbiome in mice and provides protection from experimental colitis in female offspring. FASEB Bioadv. 2022 4 2 109 120 10.1096/fba.2021‑00078 35141475
    [Google Scholar]
  42. He L. Zhou X. Liu Y. Zhou L. Li F. Fecal miR-142a-3p from dextran sulfate sodium-challenge recovered mice prevents colitis by promoting the growth of Lactobacillus reuteri. Mol. Ther. 2022 30 1 388 399 10.1016/j.ymthe.2021.08.025 34450255
    [Google Scholar]
  43. Wang T. Zheng N. Luo Q. Jiang L. He B. Yuan X. Shen L. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front. Immunol. 2019 10 1235 10.3389/fimmu.2019.01235 31214189
    [Google Scholar]
  44. Sun M. Zhang F. Yin X. Cheng B. Zhao C. Wang Y. Zhang Z. Hao H. Zhang T. Ye H. Lactobacillus reuteri F‐9‐35 prevents DSS‐Induced colitis by inhibiting proinflammatory gene expression and restoring the gut microbiota in mice. J. Food Sci. 2018 83 10 2645 2652 10.1111/1750‑3841.14326 30216448
    [Google Scholar]
  45. Wang G. Huang S. Cai S. Yu H. Wang Y. Zeng X. Qiao S. Lactobacillus reuteri ameliorates intestinal inflammation and modulates gut microbiota and metabolic disorders in dextran sulfate sodium-induced colitis in mice. Nutrients 2020 12 8 2298 10.3390/nu12082298 32751784
    [Google Scholar]
  46. Chen L Zou Y Peng J Lu F Yin Y Li F Yang J Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis. J. Immunol. Res. 2015 2015 909514 10.1155/2015/909514
    [Google Scholar]
  47. Aghamohammad S. Sepehr A. Miri S.T. Najafi S. Pourshafie M.R. Rohani M. Anti‐inflammatory and immunomodulatory effects of Lactobacillus spp. as a preservative and therapeutic agent for IBD control. Immun. Inflamm. Dis. 2022 10 6 e635 10.1002/iid3.635 35634951
    [Google Scholar]
  48. Hu T. Wang H. Xiang C. Mu J. Zhao X. Preventive effect of Lactobacillus acidophilus XY27 on DSS-induced ulcerative colitis in mice. Drug Des. Devel. Ther. 2020 14 5645 5657 10.2147/DDDT.S284422 33376308
    [Google Scholar]
  49. Wu Z. Pan D. Jiang M. Sang L. Chang B. Selenium-enriched Lactobacillus acidophilus ameliorates dextran sulfate sodium-induced chronic colitis in mice by regulating inflammatory cytokines and intestinal microbiota. Front. Med. (Lausanne) 2021 8 716816 10.3389/fmed.2021.716816 34532332
    [Google Scholar]
  50. Shin M.Y. Yong C.C. Oh S. Regulatory effect of Lactobacillus brevis Bmb6 on gut barrier functions in experimental colitis. Foods 2020 9 7 864 10.3390/foods9070864 32630643
    [Google Scholar]
  51. Ding S. Ma Y. Liu G. Yan W. Jiang H. Fang J. Lactobacillus brevis alleviates DSS-induced colitis by reprograming intestinal microbiota and influencing serum metabolome in murine model. Front. Physiol. 2019 10 1152 10.3389/fphys.2019.01152 31620010
    [Google Scholar]
  52. Wong W.Y. Chan B.D. Sham T.T. Lee M.M.L. Chan C.O. Chau C.T. Mok D.K-W. Kwan Y-W. Tai W.C-S. Lactobacillus casei strain shirota ameliorates dextran sulfate sodium-induced colitis in mice by increasing taurine-conjugated bile acids and inhibiting NF-κB signaling via stabilization of IκBα. Front. Nutr. 2022 9 816836 10.3389/fnut.2022.816836
    [Google Scholar]
  53. Su L. Ma F. An Z. Ji X. Zhang P. Yue Q. Zhao C. Sun X. Li K. Li B. Liu X. Zhao L. The metabolites of Lactobacillus fermentum F-B9-1 relieved dextran sulfate sodium-induced experimental ulcerative colitis in mice. Front. Microbiol. 2022 13 865925 10.3389/fmicb.2022.865925 35572623
    [Google Scholar]
  54. Liu Y. Zheng S. Cui J. Guo T. Zhang J. Li B. Alleviative effects of exopolysaccharide produced by lactobacillus helveticus KLDS1.8701 on dextran sulfate sodium-induced colitis in mice. Microorganisms 2021 9 10 2086 10.3390/microorganisms9102086 34683406
    [Google Scholar]
  55. Huang J. Yang Z. Li Y. Chai X. Liang Y. Lin B. Ye Z. Zhang S. Che Z. Zhang H. Zhang X. Zhang Z. Chen T. Yang W. Zeng J. Lactobacillus paracasei R3 protects against dextran sulfate sodium (DSS)-induced colitis in mice via regulating Th17/Treg cell balance. J. Transl. Med. 2021 19 1 356 10.1186/s12967‑021‑02943‑x 34407839
    [Google Scholar]
  56. Pang B. Jin H. Liao N. Li J. Jiang C. Shao D. Shi J. Lactobacillus rhamnosus from human breast milk ameliorates ulcerative colitis in mice via gut microbiota modulation. Food Funct. 2021 12 11 5171 5186 10.1039/D0FO03479G 33977948
    [Google Scholar]
  57. Lee J. Park S.B. Kim H.W. Lee H.S. Jee S.R. Lee J.H. Kim T.O. Clinical efficacy of probiotic therapy on bowel-related symptoms in patients with ulcerative colitis during endoscopic remission: An observational study. Gastroenterol. Res. Pract. 2022 2022 1 1 5 10.1155/2022/9872230 35082846
    [Google Scholar]
  58. Bjarnason I. Sission G. Hayee B.H. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 2019 27 3 465 473 10.1007/s10787‑019‑00595‑4 31054010
    [Google Scholar]
  59. Kamarli Altun H. Akal Yildiz E. Akin M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turk. J. Gastroenterol. 2019 30 4 313 320 10.5152/tjg.2019.18356 30666969
    [Google Scholar]
  60. Chen P. Xu H. Tang H. Zhao F. Yang C. Kwok L.Y. Cong C. Wu Y. Zhang W. Zhou X. Zhang H. Modulation of gut mucosal microbiota as a mechanism of probiotics‐based adjunctive therapy for ulcerative colitis. Microb. Biotechnol. 2020 13 6 2032 2043 10.1111/1751‑7915.13661 32969200
    [Google Scholar]
  61. Pilarczyk-Zurek M Wcisło M Mach T Okoń K Adamski P Heczko P Influence of Lactobacillus and Bifidobacterium combination on the gut microbiota, clinical course, and local gut inflammation in patients with ulcerative colitis: A preliminary, single-center, open-label study J. Prob. Health 2017 5 1 10.4172/2329‑8901.1000163
    [Google Scholar]
  62. Palumbo V.D. Romeo M. Gammazza A.M. Carini F. Damiani P. Damiano G. Buscemi S. Lo Monte A.I. Gerges-Geagea A. Jurjus A. Tomasello G. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2016 160 3 372 377 10.5507/bp.2016.044 27623957
    [Google Scholar]
  63. Oliva S. Di Nardo G. Ferrari F. Mallardo S. Rossi P. Patrizi G. Cucchiara S. Stronati L. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment. Pharmacol. Ther. 2012 35 3 327 334 10.1111/j.1365‑2036.2011.04939.x 22150569
    [Google Scholar]
  64. D’Incà R. Barollo M. Scarpa M. Grillo A.R. Brun P. Vettorato M.G. Castagliuolo I. Sturniolo G.C. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011 56 4 1178 1187 10.1007/s10620‑010‑1384‑1 20737210
    [Google Scholar]
  65. Hegazy S.K. El-Bedewy M.M. Effect of probiotics on pro-inflammatory cytokines and NF-κB activation in ulcerative colitis. World J. Gastroenterol. 2010 16 33 4145 4151 10.3748/wjg.v16.i33.4145 20806430
    [Google Scholar]
  66. Zocco M.A. Dal Verme L.Z. Cremonini F. Piscaglia A.C. Nista E.C. Candelli M. Novi M. Rigante D. Cazzato I.A. Ojetti V. Armuzzi A. Gasbarrini G. Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006 23 11 1567 1574 10.1111/j.1365‑2036.2006.02927.x 16696804
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128322653240925115114
Loading
Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances
Bentham Science Publishers ; https://doi.org/10.2174/0113816128322653240925115114
/content/journals/cpd/10.2174/0113816128322653240925115114
/content/journals/cpd/10.2174/0113816128322653240925115114
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: inflammation ; Ulcerative colitis ; intestinal microbiome ; fibrosis ; probiotics ; immune responses

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test